Efficacy and Safety of QD202 in Participants With Acute Ischemic Stroke Undergoing Thrombolysis Excluding Endovascular Thrombectomy
A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 120 participants.
Also called NCT07581210
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 120 participants
- Sponsor
- Shanghai QuietD Biotechnology Co., Ltd.
- Registry
-
NCT07581210
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Recruiting
Technical summary
Registry record NCT07581210. Randomized; triple masking; primary purpose treatment. Start 2025-10-14 (actual); primary completion 2026-08 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of QD202 in Participants With Acute Ischemic Stroke Undergoing Thrombolysis Excluding Endovascular Thrombectomy
- Condition
- Acute Ischemic Stroke
- Intervention (Drug)
- QD202
- Intervention (Drug)
- Placebo
- Lead sponsor
- Shanghai QuietD Biotechnology Co., Ltd.
Record details
- Record id
cardio:ct-nct07581210- Content hash
2ff50646c15129ecc537a8d6d545eb03cd6629efe9f74201039e34d5f057dd2c